Home › Companies › AKEBIA THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AKEBIA THERAPEUTICS INC.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 10, 2025: 5 items on AKEBIA THERAPEUTICS INC.’s Form 8-K, filed June 13, 2025: 3 approved · 2 passed (calculated).
Significant dissent: 1 director (20.6% against); 1 equity or compensation plan (31.9% against).
Notable dissent: 1 director (13.7% against); 1 say-on-pay vote (73.9% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AKEBIA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are AKEBIA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: John P. Butler | 130,424,556 | -- | -- | 20,706,403 | 38,964,524 | 86% | Passed (calculated) | — |
| Elect Director: Myles Wolf, M.D., M.M.Sc. | 119,938,011 | -- | -- | 31,192,948 | 38,964,524 | 79% | Passed (calculated) | — |
| 2. Proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to the plan | 102,750,481 | 48,208,800 | 171,678 | -- | 38,964,524 | 68% | Approved | — |
| 3. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers | 110,676,718 | 39,006,990 | 1,447,251 | -- | 38,964,524 | 74% | Approved | — |
| 4. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 178,590,132 | 8,896,080 | 2,609,271 | -- | -- | 95% | Approved | — |
Source: AKEBIA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
133 asset managers disclosed a vote on at least one AKEBIA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Elect two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: John P. Butler
AKEBIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: John P. Butler”): 130,424,556 for, 20,706,403 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 45 asset managers below reported 33,758,405 for, 104,299 withheld, 9,563 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,503,928 | 0 | 0 | 0 | For |
| BlackRock | 7,141,971 | 0 | 0 | 0 | For |
| Fidelity | 5,360,993 | 0 | 0 | 0 | For |
| State Street | 2,389,313 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 895,000 | 0 | 0 | 0 | For |
| Federated Hermes | 820,556 | 0 | 0 | 0 | For |
| Charles Schwab | 622,914 | 0 | 0 | 0 | For |
| Equitable | 500,416 | 0 | 0 | 0 | For |
| SEI | 478,096 | 0 | 0 | 0 | For |
| TIAA | 378,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 358,955 | 0 | 0 | 0 | For |
| Lincoln Financial | 291,407 | 0 | 0 | 0 | For |
| Goldman Sachs | 269,320 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 195,921 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 172,910 | 0 | 0 | 0 | For |
| Global X | 125,897 | 0 | 0 | 0 | For |
| Nationwide | 111,707 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 108,111 | 0 | 0 | 0 | For |
| Pacific Life | 103,851 | 0 | 0 | 0 | For |
| Northern Trust | 101,831 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 94,810 | 0 | 0 | 0 | For |
| Invesco | 92,630 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 83,919 | Withhold |
| ProShares | 79,701 | 0 | 0 | 0 | For |
| Brighthouse | 78,248 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Elect two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Myles Wolf
AKEBIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Myles Wolf, M.D., M.M.Sc.”): 119,938,011 for, 31,192,948 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 45 asset managers below reported 29,503,975 for, 4,239,146 withheld, 129,146 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,503,928 | 0 | 0 | 0 | For |
| BlackRock | 7,141,971 | 0 | 0 | 0 | For |
| Fidelity | 5,360,993 | 0 | 0 | 0 | For |
| State Street | 5,600 | 0 | 0 | 2,383,713 | Withhold |
| FRANKLIN STRATEGIC SERIES | 895,000 | 0 | 0 | 0 | For |
| Federated Hermes | 820,556 | 0 | 0 | 0 | For |
| Charles Schwab | 622,914 | 0 | 0 | 0 | For |
| Equitable | 386,066 | 0 | 0 | 114,350 | Mixed |
| SEI | 478,096 | 0 | 0 | 0 | For |
| TIAA | 378,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 358,955 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 291,407 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 269,320 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 195,921 | Withhold |
| SEI Exchange Traded Funds | 172,910 | 0 | 0 | 0 | For |
| Global X | 125,897 | 0 | 0 | 0 | For |
| Nationwide | 12,110 | 0 | 0 | 99,597 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 108,111 | Withhold |
| Pacific Life | 103,851 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 101,831 | Withhold |
| Bridge Builder Trust | 94,810 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 92,630 | Withhold |
| Dimensional | 0 | 0 | 0 | 83,919 | Withhold |
| ProShares | 0 | 0 | 0 | 79,701 | Withhold |
| Brighthouse | 0 | 0 | 0 | 78,248 | Withhold |
Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
68% Approved · of votes cast
Prior year: 46.1% for (June 6, 2024 meeting) ▲ 22.0 pts
Description as filed by funds: Approve an amendment to the Akebia Therapeutics, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to the plan;
AKEBIA THERAPEUTICS INC.’s own tally for this item (“2. Proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to ”): 102,750,481 for, 48,208,800 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to the plan was approved as follows:”
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 46 asset managers below reported 33,473,759 for, 399,051 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,503,928 | 0 | 0 | 0 | For |
| BlackRock | 7,141,971 | 0 | 0 | 0 | For |
| Fidelity | 5,360,993 | 0 | 0 | 0 | For |
| State Street | 2,389,197 | 116 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 895,000 | 0 | 0 | 0 | For |
| Federated Hermes | 820,556 | 0 | 0 | 0 | For |
| Charles Schwab | 622,914 | 0 | 0 | 0 | For |
| Equitable | 500,416 | 0 | 0 | 0 | For |
| SEI | 478,096 | 0 | 0 | 0 | For |
| TIAA | 0 | 378,555 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 358,955 | 0 | 0 | 0 | For |
| Lincoln Financial | 291,407 | 0 | 0 | 0 | For |
| Goldman Sachs | 269,320 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 195,921 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 172,910 | 0 | 0 | 0 | For |
| Global X | 125,897 | 0 | 0 | 0 | For |
| Nationwide | 111,707 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 108,111 | 0 | 0 | 0 | For |
| Pacific Life | 103,851 | 0 | 0 | 0 | For |
| Northern Trust | 101,831 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 94,810 | 0 | 0 | 0 | For |
| Invesco | 92,630 | 0 | 0 | 0 | For |
| Dimensional | 83,919 | 0 | 0 | 0 | For |
| ProShares | 79,701 | 0 | 0 | 0 | For |
| Brighthouse | 78,248 | 0 | 0 | 0 | For |
Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
74% Approved · of votes cast
Prior year: 50.8% for (June 6, 2024 meeting) ▲ 23.2 pts
Description as filed by funds: Hold an advisory vote on the compensation of Akebia's named executive officers;
AKEBIA THERAPEUTICS INC.’s own tally for this item (“3. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers”): 110,676,718 for, 39,006,990 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers was approved as follows:”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,503,928 | 0 | 0 | 0 | For |
| BlackRock | 7,141,971 | 0 | 0 | 0 | For |
| Fidelity | 5,360,993 | 0 | 0 | 0 | For |
| State Street | 2,388,573 | 740 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 895,000 | 0 | 0 | 0 | For |
| Federated Hermes | 820,556 | 0 | 0 | 0 | For |
| Charles Schwab | 622,914 | 0 | 0 | 0 | For |
| Equitable | 500,416 | 0 | 0 | 0 | For |
| SEI | 478,096 | 0 | 0 | 0 | For |
| TIAA | 378,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 358,955 | 0 | 0 | 0 | For |
| Lincoln Financial | 291,407 | 0 | 0 | 0 | For |
| Goldman Sachs | 269,320 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 195,921 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 172,910 | 0 | 0 | 0 | For |
| Global X | 125,897 | 0 | 0 | 0 | For |
| Nationwide | 111,707 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 108,111 | 0 | 0 | 0 | For |
| Pacific Life | 103,851 | 0 | 0 | 0 | For |
| Northern Trust | 101,831 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 94,810 | 0 | 0 | 0 | For |
| Invesco | 0 | 92,630 | 0 | 0 | Against |
| Dimensional | 83,919 | 0 | 0 | 0 | For |
| ProShares | 79,701 | 0 | 0 | 0 | For |
| Brighthouse | 78,248 | 0 | 0 | 0 | For |
Fund voting reports, all 45 managers: 33,758,517 for, 113,750 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 6,291,983 | 17,577 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 5,058,729 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 4,973,840 | 0 | 0 | 0 | For |
| BlackRock | 3,731,652 | 47,145 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,665,158 | 0 | 0 | 0 | For |
| Woodline Partners LP | 2,485,578 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 2,000,000 | 0 | 0 | 0 | For |
| Renaissance | 1,714,777 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,492,799 | 0 | 0 | 0 | For |
| Northern Trust | 1,408,171 | 0 | 0 | 0 | For |
| Citadel | 1,377,666 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 1,111,837 | 0 | 0 | 0 | For |
| SEI | 995,065 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 974,430 | 0 | 0 | 0 | For |
| Fidelity | 871,532 | 0 | 0 | 0 | For |
| Federated Hermes | 861,519 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 716,335 | 0 | 0 | 0 | For |
| OREGON PUBLIC EMPLOYEES RETIREMENT FUND | 689,593 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 666,684 | 0 | 0 | 0 | For |
| Charles Schwab | 622,914 | 0 | 0 | 0 | For |
| Wellington | 484,866 | 0 | 0 | 0 | For |
| Informed Momentum Co LLC | 463,556 | 0 | 0 | 0 | For |
| Nuveen | 378,555 | 0 | 0 | 0 | For |
| Invesco | 0 | 254,975 | 0 | 0 | Against |
| MACKENZIE FINANCIAL CORP | 250,744 | 0 | 0 | 0 | For |
Institutional-manager reports, all 104 managers: 44,597,588 for, 614,469 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 89.8% for (June 6, 2024 meeting) ▲ 5.4 pts
Description as filed by funds: Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and
AKEBIA THERAPEUTICS INC.’s own tally for this item (“4. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 178,590,132 for, 8,896,080 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 45 asset managers below reported 33,868,893 for, 3,374 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,503,928 | 0 | 0 | 0 | For |
| BlackRock | 7,141,971 | 0 | 0 | 0 | For |
| Fidelity | 5,360,993 | 0 | 0 | 0 | For |
| State Street | 2,389,197 | 116 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 895,000 | 0 | 0 | 0 | For |
| Federated Hermes | 820,556 | 0 | 0 | 0 | For |
| Charles Schwab | 622,914 | 0 | 0 | 0 | For |
| Equitable | 500,416 | 0 | 0 | 0 | For |
| SEI | 478,096 | 0 | 0 | 0 | For |
| TIAA | 378,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 358,955 | 0 | 0 | 0 | For |
| Lincoln Financial | 291,407 | 0 | 0 | 0 | For |
| Goldman Sachs | 269,320 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 195,921 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 172,910 | 0 | 0 | 0 | For |
| Global X | 125,897 | 0 | 0 | 0 | For |
| Nationwide | 111,707 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 108,111 | 0 | 0 | 0 | For |
| Pacific Life | 103,851 | 0 | 0 | 0 | For |
| Northern Trust | 101,831 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 94,810 | 0 | 0 | 0 | For |
| Invesco | 92,630 | 0 | 0 | 0 | For |
| Dimensional | 83,919 | 0 | 0 | 0 | For |
| ProShares | 79,701 | 0 | 0 | 0 | For |
| Brighthouse | 78,248 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 262,635,836 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.76% |
| 2 | BlackRock | 2.72% |
| 3 | Fidelity | 2.04% |
| 4 | State Street | 0.91% |
| 5 | FRANKLIN STRATEGIC SERIES | 0.34% |
| 6 | Federated Hermes | 0.31% |
| 7 | Charles Schwab | 0.24% |
| 8 | Equitable | 0.19% |
| 9 | SEI | 0.18% |
| 10 | TIAA | 0.14% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 2.40% |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 1.93% |
| 3 | GREAT POINT PARTNERS LLC | 1.89% |
| 4 | BlackRock | 1.44% |
| 5 | FRANKLIN ADVISERS INC | 1.01% |
| 6 | Woodline Partners LP | 0.95% |
| 7 | Nantahala Capital Management, LLC | 0.76% |
| 8 | Renaissance | 0.65% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.57% |
| 10 | Northern Trust | 0.54% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 15,332,163 | 5.84% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 12,685,803 | 4.83% | Form 13F, quarter ended March 31, 2025 |
| State Street | 6,805,807 | 2.59% | Form 13F, quarter ended March 31, 2025 |
| Satter Muneer A | 5,747,906 | 2.19% | Schedule 13G, filed February 14, 2025 |
| John P. Butler | 5,074,211 | 1.93% | Proxy statement (DEF 14A), table as of March 31, 2025 |
| Geode Capital | 5,030,740 | 1.92% | Form 13F, quarter ended March 31, 2025 |
| Renaissance Technologies | 4,005,827 | 1.53% | Form 13F, quarter ended March 31, 2025 |
| Citadel Advisors | 3,832,609 | 1.46% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 2,724,439 | 1.04% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 2,681,198 | 1.02% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 262,635,836 shares outstanding, as reported by AKEBIA THERAPEUTICS INC. on its Form 10-Q dated May 5, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AKEBIA THERAPEUTICS INC.'s shareholder meeting held June 10, 2025, in the 2024-2025 proxy season, 133 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 745 separate fund positions. On the most widely held item on that ballot — Hold an advisory vote on the compensation of Akebia's named executive officers; — AKEBIA THERAPEUTICS INC.'s filing reports the proposal as approved, with 74% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AKEBIA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AKEBIA THERAPEUTICS INC.’s 10-Q dated May 5, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AKEBIA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “AKEBIA THERAPEUTICS (AKBA) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/akebia-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.